Boston Scientific Q3 2026 Results: Net Income $580M, Down 23.2% YoY
Boston Scientific reported net sales of $5.138 billion for the third quarter of 2026, a slight increase from $5.065 billion in the prior year period. Net income attributable to common stockholders decreased to $582 million ($0.40 per diluted share) compared to $755 million ($0.51 per diluted share) in Q3 2025, impacted by higher operating expenses and litigation-related charges.
- Key figure
- Net income $580M · -23.2% YoY